Mineralys Therapeutics (MLYS) Current Assets (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Current Assets of $652.5 million for Q1 2026, down 1.35% sequentially from $661.4 million in Q4 2025, and up 84.05% YoY from $354.5 million in Q1 2025.
Mineralys Therapeutics (MLYS) Current Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Current Assets for 5 years, with the latest figure at $652.5 million in Q1 2026.
- Quarterly Current Assets rose 84.05% year-over-year to $652.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $652.5 million (up 84.05% YoY) and the FY2025 annual result came in at $661.4 million, up 222.08% from the prior year.
- Current Assets eased to $652.5 million in Q1 2026 per MLYS's latest filing, from $661.4 million in the prior quarter.
- Over five years, Current Assets peaked at $661.4 million in Q4 2025 and troughed at $112.8 million in Q4 2022.
- A 5-year average of $351.0 million and a median of $296.6 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2025: Current Assets dropped 17.56% in 2024, then soared 222.08% in 2025.
- Over 5 years, Current Assets stood at $112.8 million in 2022, then surged by 120.81% to $249.1 million in 2023, then dropped by 17.56% to $205.4 million in 2024, then jumped by 222.08% to $661.4 million in 2025, then slipped by 1.35% to $652.5 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $652.5 million, $661.4 million, and $599.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 665.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 665.80 Mn |
| Mar 31, 2026 | 652.47 Mn |
| Dec 31, 2025 | 661.39 Mn |
| Sep 30, 2025 | 599.80 Mn |
| Jun 30, 2025 | 335.27 Mn |
| Mar 31, 2025 | 354.51 Mn |
| Dec 31, 2024 | 205.35 Mn |
| Sep 30, 2024 | 267.73 Mn |
| Jun 30, 2024 | 318.00 Mn |
| Mar 31, 2024 | 346.82 Mn |
| Dec 31, 2023 | 249.10 Mn |
| Sep 30, 2023 | 265.38 Mn |
| Jun 30, 2023 | 269.49 Mn |
| Mar 31, 2023 | 275.27 Mn |
| Dec 31, 2022 | 112.81 Mn |